One to Watch: SGY-101 Advances Toward Clinical Trials for Fat Reduction and Tissue Remodeling
Sagesse Bio plans to rapidly develop SGY-101 with, a novel siRNA therapeutic for focal fat reduction and tissue remodeling. The Company is partnering with Gore Range Capital LLC and Sirnaomics LTD to move the needle. SGY-101 utilizes small interfering RNAs (siRNAs) to precisely target adipocytes, silencing the expression of TGF-β1 and COX-2 genes, both of which play critical […]